Atorvastatin attenuates involvement of RhoA/Rho-kinase pathway and NF-κB activation in hypoxic pulmonary hypertensive rats

Chinese Medical Journal

Volumn 127, Issue 5, 2014, Pages 869-872

  Zhang, Yan ^a   Dai, Li ^a   Wu, Shang Jie ^a   Chen, Ping ^a   Zhao, Shui Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Atorvastatin; Hypoxic pulmonary hypertension; NF B; Rho A Rho kinase; Vascular remodeling

Indexed keywords

ATORVASTATIN; MYOSIN LIGHT CHAIN PHOSPHATASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; HEPTANOIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRROLE DERIVATIVE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; HEART VENTRICLE SEPTUM; HEART WEIGHT; HYPOXIC PULMONARY HYPERTENSION; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANIMAL; ANOXIA; DRUG EFFECTS; ENZYMOLOGY; HYPERTENSION, PULMONARY; METABOLISM; RANDOMIZATION; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; ANOXIA; BLOTTING, WESTERN; HEPTANOIC ACIDS; HYPERTENSION, PULMONARY; MALE; NF-KAPPA B; PYRROLES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84896807118     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131801     Document Type: Article

References (16)

1. Vanderpool RR, Kim AR, Molthen R, Chesler NC. Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function. J Appl Physiol 2011; 110: 188-198.
2. Li XH, Peng J, Tan N, Wu WH, Li TT, Shi RZ, et al. Involvement of asymmetric dimethylarginine and Rho kinase in the vascular remodeling in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol 2010; 53: 223-229.
3. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995; 270: 29051-29054.
4. Wirth A. Rho kinase and hypertension. Biochim Biophys Acta2010; 1802: 1276-1284.
5. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol2011; 301: H287-H296.
6. Ito M, Nakano T, Erdodi F, Hartshorne DJ. Myosin phosphatase: structure, regulation and function. Mol Cell Biochem 2004; 259: 197-209.
7. Duong-Quy S, Bei Y, Liu Z, Dinh-Xuan AT. Role ofRho-kinaseand its inhibitors inpulmonary hypertension. Pharmacol Ther2013; 137: 352-364.
8. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109: 81-96.
9. He Y, Xu H, Liang L, Zhan Z, Yang X, Yu X, et al. Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum 2008; 58: 3366-3376.
10. Zeng J, Yi B, Wang Z, Ning J, Wang X, Lu K. Effect of annexin A2 on hepatopulmonary syndrome rat serum-induced proliferation ofpulmonaryarterialsmooth muscle cells. Respir Physiol Neurobiol2013; 185: 332-338.
11. Alegret M, Silvestre JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Timely Top Med Cardiovasc Dis 2007; 11: 10.
12. Carlin CM, Celnik DF, Pak O, Wadsworth R, Peacock AJ, Welsh DJ. Low-dose fluvastatin reverses the hypoxicpulmonaryadventitial fibroblast phenotype in experimentalpulmonary hypertension. Am J Respir Cell Mol Biol2012; 47: 140-148.
13. Laudi S, Trump S, Schmitz V, West J, McMurtry IF, Mutlak H, et al. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 293: 630-638.
14. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 2005; 280: 34202-34209.
15. Belaiba RS, Bonello S, Zähringer C, Schmidt S, Hess J, Kietzmann T, et al. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007; 18: 4691-4697.
16. Krymskaya VP, Snow J, Cesarone G, Khavin I, Goncharov DA, Lim PN, et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J 2011; 25: 1922-1933.